Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label LCZ696 extension study for PARADIGM-HF participants with chronic heart failure and reduced ejection fraction
NL-OMON42095Phase 3Active, not recruiting
- Sponsor
- Novartis
- Start
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of sacubitril + valsartan in heart failure with reduced ejection fraction (HFrEF) and chronic heart failure (CHF), sponsored by Novartis. Primary endpoints: All adverse events and serious adverse events, Adverse events of special interest and 2 more. Started Jan 2015; status: active, not recruiting.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure with reduced ejection fraction (HFrEF)chronic heart failure (CHF)
Beyond the preview
Go deeper on NL-OMON42095.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42095.